{
    "title": "To amend the Employee Retirement Income Security Act of 1974, the Public Health Service Act, and the Internal Revenue Code of 1986 to require group and individual health insurance coverage and group health plans to provide for coverage of oral anticancer drugs on terms no less favorable than the coverage provided for intravenously administered anticancer medications.",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Cancer Drug Coverage Parity Act of \n2011''.\n\nSEC. 2. PARITY IN COVERAGE FOR ORAL ANTICANCER DRUGS.\n\n    (a) Employee Retirement Income Security Act of 1974 Amendments.--\n(1) Subpart B of part 7 of subtitle B of title I of the Employee \nRetirement Income Security Act of 1974 is amended by adding at the end \nthe following new section:\n\n``SEC. 716. PARITY IN COVERAGE FOR ORAL ANTICANCER DRUGS.\n\n    ``(a) In General.--Subject to subsection (b), a group health plan, \nand a health insurance issuer providing health insurance coverage in \nconnection with a group health plan, that provides benefits with \nrespect to intravenously administered or injected anticancer \nmedications shall provide for no less favorable coverage for \nprescribed, orally administered anticancer medication that is used to \nkill or slow the growth of cancerous cells and that has been approved \nby the Food and Drug Administration.\n    ``(b) Limitation.--Subsection (a) shall only apply to anticancer \nmedication that is prescribed based on a finding by the treating \nphysician that the medication--\n            ``(1) is medically necessary for the purpose of killing or \n        slowing the growth of cancerous cells in a manner that is in \n        accordance with nationally accepted standards of medical \n        practice;\n            ``(2) is clinically appropriate in terms of type, \n        frequency, extent site, and duration; and\n            ``(3) is not primarily for the convenience of the patient, \n        physician, or other health care provider.\n    ``(c) Application of Cost-Sharing and Restrictions.--\n            ``(1) In general.--The coverage of anticancer medication \n        under subsection (a) may be subject to annual deductibles and \n        coinsurance or copayments so long as such deductibles, \n        coinsurance, and copayments do not exceed the deductibles, \n        coinsurance, and copayments that are applicable to \n        intravenously administered or injected anticancer medications \n        under the plan or coverage for the same purpose.\n            ``(2) Restriction.--A group health plan or health insurance \n        issuer may not, in order to comply with the requirement of \n        subsection (a)--\n                    ``(A) impose an increase in out-of-pocket costs \n                with respect to anticancer medications; or\n                    ``(B) reclassify benefits with respect to \n                anticancer medications.\n    ``(d) Application of Notice, Prohibitions, Etc.--The provisions of \nsubsections (b), (c), (d), and (e)(2) of section 713 shall apply with \nrespect to the coverage required by subsection (a) in the same manner \nas they apply with respect to the coverage required under such section, \nexcept that January 1, 2012, shall be substituted for the date referred \nto in subsection (b)(3) of such section.\n    ``(e) Construction.--Nothing in this section shall be construed--\n            ``(1) to require the use of orally administered anticancer \n        medications as a replacement for other anticancer medications; \n        or\n            ``(2) to prohibit a group health plan or health insurance \n        issuer from requiring prior authorization or imposing other \n        appropriate utilization controls in approving coverage for any \n        chemotherapy.''.\n    (2) Section 731(c) of such Act (29 U.S.C. 1191(c)) is amended by \nstriking ``section 711'' and inserting ``sections 711 and 716''.\n    (3) Section 732(a) of such Act (29 U.S.C. 1191a(a)) is amended by \nstriking ``section 711'' and inserting ``sections 711 and 716''.\n    (4) The table of contents in section 1 of such Act is amended by \ninserting after the item relating to section 714 the following new \nitems:\n\n``Sec. 715. Additional market reforms.\n``Sec. 716. Parity in coverage for oral anticancer drugs.''.\n    (b) Public Health Service Act Amendments.--(1) Title XXVII of the \nPublic Health Service Act is amended by inserting after section 2728 \n(42 U.S.C. 300gg-28), as redesignated by section 1001(2) of the Patient \nProtection and Affordable Care Act (Public Law 111-148), the following \nnew section:\n\n``SEC. 2729. PARITY IN COVERAGE FOR ORAL ANTICANCER DRUGS.\n\n    ``(a) In General.--Subject to subsection (b), a group health plan, \nand a health insurance issuer offering group or individual health \ninsurance coverage, that provides benefits with respect to \nintravenously administered or injected anticancer medications shall \nprovide for no less favorable coverage for prescribed, orally \nadministered anticancer medication that is used to kill or slow the \ngrowth of cancerous cells and that has been approved by the Food and \nDrug Administration.\n    ``(b) Limitation.--Subsection (a) shall only apply to anticancer \nmedication that is prescribed based on a finding by the treating \nphysician that the medication--\n            ``(1) is medically necessary for the purpose of killing or \n        slowing the growth of cancerous cells in a manner that is in \n        accordance with nationally accepted standards of medical \n        practice;\n            ``(2) is clinically appropriate in terms of type, \n        frequency, extent site, and duration; and\n            ``(3) is not primarily for the convenience of the patient, \n        physician, or other health care provider.\n    ``(c) Application of Cost-Sharing and Restrictions.--\n            ``(1) In general.--The coverage of anticancer medication \n        under subsection (a) may be subject to annual deductibles and \n        coinsurance or copayments so long as such deductibles, \n        coinsurance, and copayments do not exceed the deductibles, \n        coinsurance, and copayments that are applicable to \n        intravenously administered or injected anticancer medications \n        under the plan or coverage for the same purpose.\n            ``(2) Restriction.--A group health plan or health insurance \n        issuer may not, in order to comply with the requirement of \n        subsection (a)--\n                    ``(A) impose an increase in out-of-pocket costs \n                with respect to anticancer medications; or\n                    ``(B) reclassify benefits with respect to \n                anticancer medications.\n    ``(d) Application of Notice, Prohibitions, Etc.--The provisions of \nsubsections (b), (c), (d), and (e)(2) of section 713 of the Employee \nRetirement and Income Security Act of 1974 shall apply with respect to \nthe coverage required by subsection (a) in the same manner as they \napply with respect to the coverage required under such section, except \nthat January 1, 2012, shall be substituted for the date referred to in \nsubsection (b)(3) of such section.\n    ``(e) Construction.--Nothing in this section shall be construed--\n            ``(1) to require the use of orally administered anticancer \n        medications as a replacement for other anticancer medications; \n        or\n            ``(2) to prohibit a group health plan or health insurance \n        issuer from requiring prior authorization or imposing other \n        appropriate utilization controls in approving coverage for any \n        chemotherapy.''.\n    (2) Section 2724(c) of such Act (42 U.S.C. 300gg-23(c)), as \nredesignated by section 1001(4) and subsection (c)(14) of the section \n1563 (relating to conforming amendments) of Public Law 111-148, is \namended by striking ``section 2704'' and inserting ``sections 2725 and \n2729''.\n    (3) Section 2762(b)(2) of such Act (42 U.S.C. 300gg-62(b)(2)) is \namended by striking ``section 2751'' and inserting ``sections 2751 and \n2729''.\n    (4) For purposes of applying section 2729 of the Public Health \nService Act, as inserted by paragraph (1), to individual health \ninsurance coverage before 2014, the provisions of such section shall be \ntreated as also included under part B of title XXVII of the Public \nHealth Service Act.\n    (c) Internal Revenue Code Amendments.--\n            (1) In general.--Subchapter B of chapter 100 of the \n        Internal Revenue Code of 1986, as amended by subsection (f) of \n        the section 1563 (relating to conforming amendments) of Public \n        Law 111-148, is amended by adding at the end the following new \n        section:\n\n``SEC. 9816. PARITY IN COVERAGE FOR ORAL ANTICANCER DRUGS.\n\n    ``(a) In General.--Subject to subsection (b), a group health plan \nthat provides benefits with respect to intravenously administered or \ninjected anticancer medications shall provide for no less favorable \ncoverage for prescribed, orally administered anticancer medication that \nis used to kill or slow the growth of cancerous cells and that has been \napproved by the Food and Drug Administration.\n    ``(b) Limitation.--Subsection (a) shall only apply to anticancer \nmedication that is prescribed based on a finding by the treating \nphysician that the medication--\n            ``(1) is medically necessary for the purpose of killing or \n        slowing the growth of cancerous cells in a manner that is in \n        accordance with nationally accepted standards of medical \n        practice;\n            ``(2) is clinically appropriate in terms of type, \n        frequency, extent site, and duration; and\n            ``(3) is not primarily for the convenience of the patient, \n        physician, or other health care provider.\n    ``(c) Application of Cost-Sharing and Restrictions.--\n            ``(1) In general.--The coverage of anticancer medication \n        under subsection (a) may be subject to annual deductibles and \n        coinsurance or copayments so long as such deductibles, \n        coinsurance, and copayments do not exceed the deductibles, \n        coinsurance, and copayments that are applicable to \n        intravenously administered or injected anticancer medications \n        under the plan for the same purpose.\n            ``(2) Restriction.--A group health plan may not, in order \n        to comply with the requirement of subsection (a)--\n                    ``(A) impose an increase in out-of-pocket costs \n                with respect to anticancer medications; or\n                    ``(B) reclassify benefits with respect to \n                anticancer medications.\n    ``(d) Application of Notice, Prohibitions, Etc.--The provisions of \nsubsections (b), (c), (d), and (e)(2) of section 713 of the Employee \nRetirement and Income Security Act of 1974 shall apply with respect to \nthe coverage required by subsection (a) in the same manner as they \napply with respect to the coverage required under such section, except \nthat January 1, 2012, shall be substituted for the date referred to in \nsubsection (b)(3) of such section.\n    ``(e) Construction.--Nothing in this section shall be construed--\n            ``(1) to require the use of orally administered anticancer \n        medications as a replacement for other anticancer medications; \n        or\n            ``(2) to prohibit a group health plan or health insurance \n        issuer from requiring prior authorization or imposing other \n        appropriate utilization controls in approving coverage for any \n        chemotherapy.''.\n            (2) Clerical amendment.--The table of sections for such \n        subchapter is amended by adding at the end the following new \n        items:\n\n``Sec. 9815. Additional market reforms.\n``Sec. 9816. Parity in coverage for oral anticancer drugs.''.\n    (d) Clarifying Amendment Regarding Application to Grandfathered \nPlans.--Section 1251(a)(4)(A) of the Patient Protection and Affordable \nCare Act (Public Law 111-148; 42 U.S.C. 18011(a)(4)(A)), as added by \nsection 2301(a) of Public Law 111-152, is amended by adding at the end \nthe following new clause:\n                            ``(v) Section 2729 (relating to standards \n                        relating to benefits for minor child's \n                        congenital or developmental deformity or \n                        disorder), as added by section 2(b) of the \n                        Cancer Drug Coverage Parity Act of 2011.''.\n    (e) Effective Date.--The amendments made by this section shall \napply with respect to group health plans for plan years beginning on or \nafter January 1, 2012, and with respect to health insurance coverage \noffered, sold, issued, renewed, in effect, or operated in the \nindividual market on or after such date.\n    (f) Study.--Not later than 2 years after the date of the enactment \nof this Act--\n            (1) the Medicare Payment Advisory Commission shall complete \n        a study that assesses how closing the Medicare part D donut \n        hole under the amendments made by section 3301 of the Patient \n        Protection and Affordable Care Act (Public Law 111-148), as \n        amended by section 1101 of the Health Care and Education \n        Reconciliation Act of 2010 (Public Law 111-152), affects \n        Medicare coverage for orally administered anticancer \n        medications, with a particular focus on cost and accessibility; \n        and\n            (2) submit a report to Congress on the results of such \n        study."
}